Aug 2018 $7 M No. 7 $2 to $10 million 1
Caldera Pharmaceuticals Inc: Raise no. 7, Aug 2018 × Investors in this round 1 investor had bought by the notice of Sep 12, 2018: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Caldera Pharmaceuticals Inc as a whole in other filings: see Investors below.
What the notice says
Amount sold $7 M of $7 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees $307,500
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Douglas Krafte · Executive Officer Mark Korb · Executive Officer Richard Cunningham · Executive Officer Clive Kabatznik · Director Edward Roffman · Director Michael Taglich · Director Timothy Tyson · Director Vincent Palmieri · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Proceeds may be used to pay overhead and other corporate expenses which could include salaries.”Signed by Richard Cunningham, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 12, 2018. Read the notice at the SEC .
debt, options SEC Apr 2018 $2 M No. 6 $2 to $10 million 1
Caldera Pharmaceuticals Inc: Raise no. 6, Apr 2018 × Investors in this round 1 investor had bought by the notice of Apr 12, 2018: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Caldera Pharmaceuticals Inc as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $4 M offered; $2 M still to sell
Smallest investment taken $100,000
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Mark Korb · Executive Officer Richard Cunningham · Executive Officer Clive Kabatznik · Director Douglas Krafte · Director Edward Roffman · Director Michael Taglich · Director Timothy Tyson · Director Vincent Palmieri · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “*Proceeds may be used to pay overhead and other corporate expenses which could includesalaries”Signed by Richard Cunningham, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 12, 2018. Read the notice at the SEC .
equity, options SEC Apr 2017 $2 M No. 5 Under $2 million 3
Caldera Pharmaceuticals Inc: Raise no. 5, Apr 2017 × Investors in this round 3 investors had bought by the notice of Apr 28, 2017: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Caldera Pharmaceuticals Inc as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken $500,000
What was sold debt, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $60,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Douglas Krafte · Executive Officer Mark Korb · Executive Officer Richard Cunningham · Executive Officer Benjamin Warner · Director Clive Kabatznik · Director Edward Roffman · Director Michael Taglich · Director Timothy Tyson · Director Vincent Palmieri · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round "TAGLICH BROTHERS, INC. (""TAGLICH"")" (CRD 29102) · New York, New York Sold in CT, NY Remarks in the notice On fees: “*Designees of Taglich also received a warrant to acquire 25,000 shares of common stock as compensation”On the amounts: “*The amount being raised was a minimum of $1,000,000”On the use of proceeds: “*Proceeds may be used to pay overhead and other corporate expenses which could include salaries”Signed by Richard Cunningham, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 28, 2017. Read the notice at the SEC .
debt, options SEC Jun 2016 $1 M No. 4 Under $2 million 12
Caldera Pharmaceuticals Inc: Raise no. 4, Jun 2016 × Investors in this round 12 investors had bought by the notice of Jul 8, 2016: 12 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Caldera Pharmaceuticals Inc as a whole in other filings: see Investors below.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken $10,000
What was sold debt, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $68,700
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Douglas Krafte · Executive Officer Mark Korb · Executive Officer Richard Cunningham · Executive Officer Benjamin Warner · Director Clive Kabatznik · Director Edward Roffman · Director Michael Taglich · Director Timothy Tyson · Director Vincent Palmieri · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Taglich Brothers, Inc. (CRD 29102) · New York, New York Sold in CA, FL, KS, MI, NY Remarks in the notice On the amounts: “*The amount being raised was a minimum of $1,000,000”Signed by Richard Cunningham, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 8, 2016. Read the notice at the SEC .
debt, options SEC Dec 2014 $9 M No. 3 $2 to $10 million 162
Caldera Pharmaceuticals Inc: Raise no. 3, Dec 2014 × Investors in this round 162 investors had bought by the notice of Jan 15, 2015: 162 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Caldera Pharmaceuticals Inc as a whole in other filings: see Investors below.
What the notice says
Amount sold $9 M of $9 M offered
Smallest investment taken $10,000
What was sold equity, options or other rights to buy securities, other: Warrant is exercisable for Common Stock Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $708,400
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Benjamin Warner · Executive Officer, Director Mark Korb · Executive Officer Richard Cunningham · Executive Officer Clive Kabatznik · Director Edward Roffman · Director Michael Taglich · Director Timothy Tyson · Director Vincent Palmieri · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Taglich Brothers, Inc. (CRD 29102) · New York, New York Sold in AZ, CA, CO, CT, FL, GA, IA, IL, IN, KS, MA, MD, MI, MN, MO, NC, NH, NJ, NV, NY, OH, OK, PA, SC, SD, TN, TX, VA, WA, WI Signed by Richard Cunningham, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 15, 2015. Read the notice at the SEC .
equity, options SEC Apr 2013 $3 M No. 2 $2 to $10 million 61
Caldera Pharmaceuticals Inc: Raise no. 2, Apr 2013 × Investors in this round 61 investors had bought by the notice of May 10, 2013: 61 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Caldera Pharmaceuticals Inc as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $5 M offered; $2 M still to sell
Smallest investment taken $10,000
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $282,150
Finders' fees none
Paid to its own people $250,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Benjamin Warner · Executive Officer, Director Edward Roffman · Director Jeremiel Zimmerman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round VINCENT PALMIERI · broker-dealer Taglich Brothers, Inc. (CRD 29102) · Huntington, New York Sold in AR, CA, CO, CT, IA, IN, KS, KY, ME, MI, MN, MO, NC, NE, NH, NM, NY, OH, OK, PA, SC, TN, WI Remarks in the notice On fees: “Includes value of warrants to purchase common shares issued without consideration.”On the amounts: “Includes $375,000 of convertible debt that converted into 150,000 units in the offering”Signed by Benjamin Warner, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed May 10, 2013. Read the notice at the SEC .
equity, options SEC May 2011 $1 M No. 1 Under $2 million 0
Caldera Pharmaceuticals Inc: Raise no. 1, May 2011 × Investors in this round 0 investors had bought by the notice of May 19, 2011: 0 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Caldera Pharmaceuticals Inc as a whole in other filings: see Investors below.
What the notice says
Amount sold $1 M of $2 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Benjamin Warner · Executive Officer, Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Benjamin Warner, Ceo. Source: SEC Form D, newest notice filed May 19, 2011. Read the notice at the SEC .
equity, options SEC